{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:44:05Z","timestamp":1790999045550,"version":"4.1.0"},"reference-count":101,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICI) are being increasingly used to successfully treat several types of cancer. However, due to their mode of action, these treatments are associated with several immune-related adverse events (irAEs), including immune-mediated autoimmune-like hepatitis in 5 to 10% of cases. The specific immune mechanism responsible for the development of immune-mediated liver injury caused by immune checkpoint inhibitors (ILICI) is currently unknown. This review summarizes the current knowledge on hepatic irAEs during cancer immunotherapy. It also addresses the clinical management of ILICI and how it is becoming an increasingly important clinical issue. Clinical, histological, and laboratory features of autoimmune hepatitis (AIH) and ILICI are compared, and their shared and distinctive traits are discussed in an effort to better understand the development of hepatic irAEs. Finally, based on the current knowledge of liver immunology and AIH pathogenesis, we propose a series of events that could trigger the observed liver injury in ICI-treated patients. This model could be useful in the design of future studies aiming to identify the specific immune mechanism(s) at play in ILICI and improve immune checkpoint inhibitor cancer immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2022.907591","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T08:59:46Z","timestamp":1656579586000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":53,"title":["Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology"],"prefix":"10.3389","volume":"13","author":[{"given":"Julian","family":"Hercun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bilodeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Lapierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"102514","DOI":"10.1016\/j.jaut.2020.102514","article-title":"Best Practices for Detection, Assessment and Management of Suspected Immune-Mediated Liver Injury Caused by Immune Checkpoint Inhibitors During Drug Development","volume":"114","author":"Regev","year":"2020","journal-title":"J Autoimmun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab Plus Dacarbazine for Previously Untreated Metastatic Melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1985","article-title":"Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study","volume":"35","author":"Hammers","year":"2017","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of Resuming Anti-PD-1 in Patients With Immune-Related Adverse Events (irAEs) During Combined Anti-CTLA-4 and Anti-PD1 in Metastatic Melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"100170","DOI":"10.1016\/j.jhepr.2020.100170","article-title":"Liver Toxicity as a Limiting Factor to the Increasing Use of Immune Checkpoint Inhibitors","volume":"2","author":"De Martin","year":"2020","journal-title":"JHEP Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40425-017-0298-2","article-title":"Safety in Treatment of Hepatocellular Carcinoma With Immune Checkpoint Inhibitors as Compared to Melanoma and non-Small Cell Lung Cancer","volume":"5","author":"Brown","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-Related Adverse Events of Checkpoint Inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96798","article-title":"Early B Cell Changes Predict Autoimmunity Following Combination Immune Checkpoint Blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival With Ipilimumab in Patients With Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.09.022","article-title":"Increased Reporting of Fatal Hepatitis Associated With Immune Checkpoint Inhibitors","volume":"123","author":"Vozy","year":"2019","journal-title":"Eur J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of Toxicities From Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2018-101146","article-title":"Immunotherapy-Related Hepatitis: Real-World Experience From a Tertiary Centre","volume":"10","author":"Cheung","year":"2019","journal-title":"Frontline Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15413","article-title":"Liver Injury is Most Commonly Due to Hepatic Metastases Rather Than Drug Hepatotoxicity During Pembrolizumab Immunotherapy","volume":"50","author":"Tsung","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03448-8","article-title":"Clinical Features of Immune-Mediated Hepatotoxicity Induced by Immune Checkpoint Inhibitors in Patients With Cancers","volume":"147","author":"Yamamoto","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-013-9939-6","article-title":"Ipilimumab Associated Hepatitis: Imaging and Clinicopathologic Findings","volume":"31","author":"Kim","year":"2013","journal-title":"Invest New Drugs"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-012-2140-5","article-title":"Pathologic Changes in Ipilimumab-Related Hepatitis in Patients With Metastatic Melanoma","volume":"57","author":"Kleiner","year":"2012","journal-title":"Dig Dis Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000453","article-title":"Ipilimumab-Associated Hepatitis: Clinicopathologic Characterization in a Series of 11 Cases","volume":"39","author":"Johncilla","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of Liver Injury Induced by Cancer Immunotherapy Using Immune Checkpoint Inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-00653-1","article-title":"Liver Biopsy Findings in Patients on Immune Checkpoint Inhibitors","volume":"34","author":"Cohen","year":"2021","journal-title":"Mod Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of Immune Checkpoint Inhibitors: A Histology Study of Seven Cases in Comparison With Autoimmune Hepatitis and Idiosyncratic Drug-Induced Liver Injury","volume":"31","author":"Zen","year":"2018","journal-title":"Modern Pathol Off J United States Can Acad Pathol Inc"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000268","article-title":"Severe Steroid-Resistant Anti-PD1 T-Cell Checkpoint Inhibitor-Induced Hepatotoxicity Driven by Biliary Injury","volume":"2","author":"Doherty","year":"2017","journal-title":"ESMO Open"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw649","article-title":"Nivolumab-Induced Cholangitic Liver Disease: A Novel Form of Serious Liver Injury","volume":"28","author":"Gelsomino","year":"2017","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab Monotherapy in Patients With Pretreated Advanced Melanoma: A Randomised, Double-Blind, Multicentre, Phase 2, Dose-Ranging Study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/CMR.0b013e32835c7e68","article-title":"Elevated Rates of Transaminitis During Ipilimumab Therapy for Metastatic Melanoma","volume":"23","author":"Bernardo","year":"2013","journal-title":"Melanoma Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.08.014","article-title":"Incidence of Grade 3-4 Liver Injury Under Immune Checkpoints Inhibitors: A Retrospective Study","volume":"69","author":"Parlati","year":"2018","journal-title":"J Hepatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in Patients With Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, non-Comparative, Phase 1\/2 Dose Escalation and Expansion Trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and Safety of Nivolumab, an Anti-PD-1 Immune Checkpoint Inhibitor, for Patients With Advanced, Refractory Squamous non-Small-Cell Lung Cancer (CheckMate 063): A Phase 2, Single-Arm Trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab Versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab Versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab Versus Chemotherapy in Patients With Advanced Melanoma Who Progressed After Anti-CTLA-4 Treatment (CheckMate 037): A Randomised, Controlled, Open-Label, Phase 3 Trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in Previously Untreated Melanoma Without BRAF Mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.650292","article-title":"Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis","volume":"11","author":"Fu","year":"2021","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib (KEYNOTE-224): A non-Randomised, Open-Label Phase 2 Trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I\/II Study","volume":"39","author":"Kelley","year":"2021","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30678","article-title":"Risk of Hepatotoxicity in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis of Published Data","volume":"141","author":"Wang","year":"2017","journal-title":"Int J Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and Ipilimumab Versus Ipilimumab in Untreated Melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders or Major Toxicity With Ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14489","article-title":"Immune-Related Hepatitis Related to Checkpoint Inhibitors: Clinical and Prognostic Factors","volume":"40","author":"Riveiro-Barciela","year":"2020","journal-title":"Liver Int"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1097\/RHU.0000000000001777","article-title":"Autoantibodies in Patients With Immune-Related Adverse Events From Checkpoint Inhibitors: A Systematic Literature Review","volume":"28","author":"Ghosh","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and Efficacy of Anti-Programmed Death 1 Antibodies in Patients With Cancer and Pre-Existing Autoimmune or Inflammatory Disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2134-z","article-title":"Ipilimumab in Metastatic Melanoma Patients With Pre-Existing Autoimmune Disorders","volume":"67","author":"Kahler","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.7326\/M17-2073","article-title":"Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/art.41068","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32215","article-title":"Effect of Corticosteroid Dosing on Outcomes in High-Grade Immune Checkpoint Inhibitor Hepatitis","volume":"75","author":"Li","year":"2021","journal-title":"Hepatology"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.11.015","article-title":"Managing Immune Checkpoint-Inhibitor-Induced Severe Autoimmune-Like Hepatitis by Liver-Directed Topical Steroids","volume":"66","author":"Ziemer","year":"2017","journal-title":"J Hepatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.034","article-title":"Immune-Related Hepatitis With Immunotherapy: Are Corticosteroids Always Needed","volume":"69","author":"Gauci","year":"2018","journal-title":"J Hepatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.03.050","article-title":"Retreatment With Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study","author":"Riveiro-Barciela","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001322","article-title":"When Steroids are Not Enough in Immune-Related Hepatitis: Current Clinical Challenges Discussed on the Basis of a Case Report","volume":"8","author":"Ziogas","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31396","article-title":"Severe Refractory Checkpoint Inhibitor-Related Hepatitis Reversed With Anti-Thymocyte Globulin and N-Acetylcysteine","volume":"72","author":"Motomura","year":"2020","journal-title":"Hepatology"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2206","article-title":"Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy","volume":"29","author":"Chmiel","year":"2011","journal-title":"J Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2107-7","article-title":"Anti-PD-1-Induced High-Grade Hepatitis Associated With Corticosteroid-Resistant T Cells: A Case Report","volume":"67","author":"McGuire","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B58","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40425-019-0532-1","article-title":"Acute Liver Injury in the Context of Immune Checkpoint Inhibitor-Related Colitis Treated With Infliximab","volume":"7","author":"Zhang","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.9851-17","article-title":"Nivolumab Induces Sustained Liver Injury in a Patient With Malignant Melanoma","volume":"57","author":"Matsubara","year":"2018","journal-title":"Intern Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.06.012","article-title":"Mortality Due to Immunotherapy Related Hepatitis","volume":"69","author":"Bhave","year":"2018","journal-title":"J Hepatol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31629","article-title":"High-Dose Glucocorticoids for the Treatment of Ipilimumab-Induced Hypophysitis is Associated With Reduced Survival in Patients With Melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.clinthera.2018.11.004","article-title":"Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients With Melanoma Treated With Nivolumab: A Multicenter Retrospective Study","volume":"41","author":"Okada","year":"2019","journal-title":"Clin Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.10.003","article-title":"Mechanisms of Immune Checkpoint Inhibitor-Mediated Liver Injury","volume":"11","author":"Shojaie","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"B66","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nri724","article-title":"Epitope Spreading in Immune-Mediated Diseases: Implications for Immunotherapy","volume":"2","author":"Vanderlugt","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.semcancer.2019.01.006","article-title":"Cancer Immunotherapy With Check Point Inhibitor can Cause Autoimmune Adverse Events Due to Loss of Treg Homeostasis","volume":"64","author":"Kumar","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s40425-019-0711-0","article-title":"Concurrent Therapy With Immune Checkpoint Inhibitors and TNFalpha Blockade in Patients With Gastrointestinal Immune-Related Adverse Events","volume":"7","author":"Badran","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21060","article-title":"The Liver as an Immunological Organ","volume":"43","author":"Racanelli","year":"2006","journal-title":"Hepatology"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1051\/medsci\/20072311985","article-title":"[The Liver: An Organ of the Immune System","volume":"23","author":"Lapierre","year":"2007","journal-title":"Med Sci (Paris)"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.9.5430","article-title":"Antigen-Specific Primary Activation of CD8+ T Cells Within the Liver","volume":"166","author":"Bertolino","year":"2001","journal-title":"J Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.3.1689","article-title":"Local Intrahepatic CD8+ T Cell Activation by a Non-Self-Antigen Results in Full Functional Differentiation","volume":"177","author":"Wuensch","year":"2006","journal-title":"J Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200421593","article-title":"The Site of Primary T Cell Activation is a Determinant of the Balance Between Intrahepatic Tolerance and Immunity","volume":"114","author":"Bowen","year":"2004","journal-title":"J Clin Invest"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/nri2858","article-title":"Antigen-Presenting Cell Function in the Tolerogenic Liver Environment","volume":"10","author":"Thomson","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.4.2402","article-title":"TNF-Alpha Controls Intrahepatic T Cell Apoptosis and Peripheral T Cell Numbers","volume":"173","author":"Murray","year":"2004","journal-title":"J Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.9.5222","article-title":"Passive and Active Mechanisms Trap Activated CD8+ T Cells in the Liver","volume":"172","author":"John","year":"2004","journal-title":"J Immunol"},{"key":"B77","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.163.6.3202","article-title":"Selective Retention of Activated CD8+ T Cells by the Normal Liver","volume":"163","author":"Mehal","year":"1999","journal-title":"J Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119468","article-title":"A Minimal Role for Selectins in the Recruitment of Leukocytes Into the Inflamed Liver Microvasculature","volume":"99","author":"Wong","year":"1997","journal-title":"J Clin Invest"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(94)80016-2","article-title":"The Liver Eliminates T Cells Undergoing Antigen-Triggered Apoptosis In Vivo","volume":"1","author":"Huang","year":"1994","journal-title":"Immunity"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.06.007","article-title":"Rules of Recruitment for Th1 and Th2 Lymphocytes in Inflamed Liver: A Role for Alpha-4 Integrin and Vascular Adhesion Protein-1","volume":"23","author":"Bonder","year":"2005","journal-title":"Immunity"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.4.1362.004k17_1362_1369","article-title":"Migration of Activated CD8(+) T Lymphocytes to Sites of Viral Infection Does Not Require Endothelial Selectins","volume":"95","author":"Bartholdy","year":"2000","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.2353\/ajpath.2006.050875","article-title":"Kupffer Cell-Dependent Hepatitis Occurs During Influenza Infection","volume":"168","author":"Polakos","year":"2006","journal-title":"Am J Pathol"},{"key":"B83","first-page":"595","article-title":"Liver Involvement in Celiac Disease","volume":"99","author":"Rubio-Tapia","year":"2008","journal-title":"Minerva Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"642923","DOI":"10.1155\/2012\/642923","article-title":"Liver Disorders in Inflammatory Bowel Disease","volume":"2012","author":"Uko","year":"2012","journal-title":"Gastroenterol Res Pract"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2896809","DOI":"10.1155\/2017\/2896809","article-title":"Possible Involvement of Liver Resident Macrophages (Kupffer Cells) in the Pathogenesis of Both Intrahepatic and Extrahepatic Inflammation","volume":"2017","author":"Kakinuma","year":"2017","journal-title":"Can J Gastroenterol Hepatol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1034\/j.1600-0528.2002.017412.x","article-title":"The Liver as a Site of T-Cell Apoptosis: Graveyard, or Killing Field","volume":"174","author":"Crispe","year":"2000","journal-title":"Immunol Rev"},{"key":"B88","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nri981","article-title":"Hepatic T Cells and Liver Tolerance","volume":"3","author":"Crispe","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41419-018-0935-9","article-title":"TNFalpha Sensitizes Hepatocytes to FasL-Induced Apoptosis by NFkappaB-Mediated Fas Upregulation","volume":"9","author":"Faletti","year":"2018","journal-title":"Cell Death Dis"},{"key":"B90","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cytogfr.2011.01.001","article-title":"Regulation of Hepatocyte Fate by Interferon-Gamma","volume":"22","author":"Horras","year":"2011","journal-title":"Cytokine Growth Factor Rev"},{"key":"B91","doi-asserted-by":"publisher","first-page":"103040","DOI":"10.1016\/j.ebiom.2020.103040","article-title":"Efficacy of Nivolumab and Ipilimumab in Patients With Malignant Pleural Mesothelioma is Related to a Subtype of Effector Memory Cytotoxic T Cells: Translational Evidence From Two Clinical Trials","volume":"62","author":"Mankor","year":"2020","journal-title":"EBioMedicine"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20585","article-title":"Lymphocyte Traffic Through Sinusoidal Endothelial Cells is Regulated by Hepatocytes","volume":"41","author":"Edwards","year":"2005","journal-title":"Hepatology"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.2.983","article-title":"Vascular Adhesion Protein-1 Mediates Adhesion and Transmigration of Lymphocytes on Human Hepatic Endothelial Cells","volume":"169","author":"Lalor","year":"2002","journal-title":"J Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.02.008","article-title":"Activation and Transcriptional Profile of Monocytes and CD8(+) T Cells are Altered in Checkpoint Inhibitor-Related Hepatitis","volume":"75","author":"Gudd","year":"2021","journal-title":"J Hepatol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27549","article-title":"Treatment of PD-1(-\/-) Mice With Amodiaquine and Anti-CTLA4 Leads to Liver Injury Similar to Idiosyncratic Liver Injury in Patients","volume":"61","author":"Metushi","year":"2015","journal-title":"Hepatology"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.5b00137","article-title":"The Role of CD8 T Cells in Amodiaquine-Induced Liver Injury in PD1-\/- Mice Cotreated With Anti-CTLA-4","volume":"28","author":"Mak","year":"2015","journal-title":"Chem Res Toxicol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217276","article-title":"Inhibition of Immune Checkpoints PD-1, CTLA-4, and IDO1 Coordinately Induces Immune-Mediated Liver Injury in Mice","volume":"14","author":"Affolter","year":"2019","journal-title":"PLos One"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.5b00305","article-title":"The Combination of Anti-CTLA-4 and PD1-\/- Mice Unmasks the Potential of Isoniazid and Nevirapine To Cause Liver Injury","volume":"28","author":"Mak","year":"2015","journal-title":"Chem Res Toxicol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.0c00485","article-title":"Liver Injury Caused by Green Tea Extract in PD-1(-\/-) Mice: An Impaired Immune Tolerance Model for Idiosyncratic Drug-Induced Liver Injury","volume":"34","author":"Cho","year":"2021","journal-title":"Chem Res Toxicol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0174","article-title":"Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade","volume":"23","author":"Reynolds","year":"2018","journal-title":"Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2006.11.010","article-title":"Pathogenesis of Autoimmune Hepatitis: From Break of Tolerance to Immune-Mediated Hepatocyte Apoptosis","volume":"149","author":"Lapierre","year":"2007","journal-title":"Transl Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.907591\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T05:01:33Z","timestamp":1676005293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.907591\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":101,"alternative-id":["10.3389\/fimmu.2022.907591"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.907591","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]},"article-number":"907591"}}